Andres Forero-Torres

Andres Forero-Torres

Auto-generated profile, based on publicly available information

Andres Forero-Torres

Kirklin UAB Hematology Oncology, Birmingham, AL

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
STSara M. Tolaney
Sara M. Tolaney
NTNabihah Tayob
Nabihah Tayob
CDChau Dang
Chau Dang
DYDenise A. Yardley
Denise A. Yardley
SISteven J. Isakoff
Steven J. Isakoff
IKIan Krop
Ian Krop
PURPOSE: The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients with stage I human epidermal growth factor receptor 2–positive (HER2+) breast cancer (BC). METHODS: Patients with stage I centrally confirmed HER2+ BC were randomly assigned 3:1 to T-DM1 or TH and received T-DM1 3.6 mg/kg IV every 3 weeks for 17 cycles or T 80 mg/m2 IV with H once every week × 12 weeks (4 mg/kg load →2 mg/kg), followed by H × 39 weeks (6 mg/kg once every 3 weeks). The co-primary objectives were to compare the incidence of clinically relevant toxicities (CRTs) in patients treated with T-DM1 versus TH and to evaluate iDFS in patients receiving T-DM1. RESULTS: The analysis population includes all 497 patients who initiated protocol therapy (383 T-DM1 and 114 TH). CRTs were experienced by 46% of patients on T-DM1 and 47% of patients on TH ( P = .83). The 3-year iDFS for T-DM1 was 97.8% (95% CI, 96.3 to 99.3), which rejected the null hypothesis ( P < .0001). Serially collected patient-reported outcomes indicated that patients treated with T-DM1 had less neuropathy and alopecia and better work productivity compared with patients on TH. CONCLUSION: Among patients with stage I HER2+ BC, one year of adjuvant T-DM1 was associated with excellent 3-year iDFS, but was not associated with fewer CRT compared with TH.

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SVShaveta Vinayak
Shaveta Vinayak
STSara M. Tolaney
Sara M. Tolaney
LSLee Steven Schwartzberg
Lee Steven Schwartzberg
MMMonica M. Mita
Monica M. Mita
GMGeorgia Anne-Lee McCann
Georgia Anne-Lee McCann
MTMelinda L. Telli
Melinda L. Telli
1011Background: Chemotherapy is a standard of care for TNBC despite its suboptimal efficacy. ≈15–20% of TNBC have BRCA1/2 mutations (mut); ≈75% of BRCA1 mut BCs are TN. Single agent poly(ADP-ribose) polymerase (PARP) inhibitors have clinical activity in pts with BRCA1/2 mutations (BRCAmut) BC and provide median PFS of 6 mos in pts with BRCAmut TNBC vs 3.5 mos for chemotherapy. Single-agent pembrolizumab (pembro), a programmed death 1(PD–1) inhibitor, has shown objective response rates (ORR) of 5–18% in previously treated TNBC. TOPACIO (NCT02657889) is a fully enrolled study evaluating the safety and efficacy of combination treatment with selective PARP1/2 inhibitor niraparib + pembro in pts with met TNBC. Methods: Pts received niraparib 200 mg orally once daily + pembro 200 mg IV on day 1 of each 21-day cycle. Primary efficacy endpoint was ORR and secondary endpoints included disease control rate (DCR = CR+PR+SD [stable disease]). Results: As of Jan 2018, 12 of 54 enrolled TNBC pts (22%) had deleterious B...

1 November 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
PTPaolo Tarantino
Paolo Tarantino
NTNabihah Tayob
Nabihah Tayob
GVGuillermo Villacampa
Guillermo Villacampa
CDChau Dang
Chau Dang
DYDenise A. Yardley
Denise A. Yardley
YZYue Zheng
Yue Zheng
PURPOSE: Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)–positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need. METHODS: In the ATEMPT phase II trial, patients with stage I centrally confirmed HER2-positive breast cancer were randomly assigned 3:1 to adjuvant T-DM1 for 1 year or paclitaxel plus trastuzumab (TH). Coprimary objectives were to compare the incidence of clinically relevant toxicities between arms and to evaluate invasive disease-free survival (iDFS) with T-DM1. Correlative analyses included the HER2DX genomic tool, multiomic evaluations of HER2 heterogeneity, and predictors of thrombocytopenia. RESULTS: After a median follow-up of 5.8 years, 11 iDFS events were observed in the T-DM1 arm, consistent with a 5-year iDFS of 97.0% (95% CI, 95.2 to 98.7). At 5 years, the recurrence-free interval (RFI) was 98.3% (95% CI, 97.0 to 99.7), the overall survival was 97.8% (95% CI, 96.3 to 99.3), and the breast cancer-specific survival was 99.4% (95% CI, 98.6 to 100). Comparable iDFS was observed with T-DM1 irrespective of tumor size, hormone receptor status, centrally determined HER2 immunohistochemical score, and receipt of T-DM1 for more or less than 6 months. Although ATEMPT was not powered for this end point, the 5-year iDFS in the TH arm was 91.1%. Among patients with sufficient tissue for HER2DX testing (n = 187), 5-year outcomes significantly differed according to HER2DX risk score, with better RFI (98.1% v 81.8%, hazard ratio [HR], 0.10, P = .01) and iDFS (96.3% v 81.8%, HR, 0.20, P = .047) among patients with HER2DX low-risk versus high-risk tumors, respectively. CONCLUSION: Adjuvant T-DM1 for 1 year leads to outstanding long-term outcomes for patients with stage I HER2-positive breast cancer. A high HER2DX risk score predicted a higher risk of recurrence in ATEMPT.

25 August 2020 in Leukemia & Lymphoma
Verified
Journal Article
Open access
DSDavid Straus
David Straus
GCGraham Collins
Graham Collins
JWJan Walewski
Jan Walewski
PZPier Luigi Zinzani
Pier Luigi Zinzani
AGAndrew Grigg
Andrew Grigg
Andrea GallaminiAndrea Gallamini
Andrea Gallamini
We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP, N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) in the ECHELON-1 study of previously untreated stage III/IV classical Hodgkin lymphoma. G-PP was associated with lower incidence of ≥ grade 3 neutropenia (29% versus 70%) and febrile neutropenia (11% versus 21%). Fewer dose delays (35% versus 49%), reductions (20% versus 26%), and hospitalizations (29% versus 38%) were observed. Seven neutropenia-associated deaths occurred in the A + AVD arm; none received G-PP. A + AVD with G-PP was associated with decreased risk of a modified progression-free survival event by 26% compared with A + AVD alone (95% CI: 0.40–1.37). G-PP reduced the rate and severity of adverse events, including febrile neutropenia, reduced treatment delays, dose reductions, and discontinuations, and may thus improve efficacy outcomes. These data support G-PP for all patients treated with A + AVD.

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AFAndres Forero-Torres
Andres Forero-Torres
HHHeather Han
Heather Han
EDElizabeth Claire Dees
Elizabeth Claire Dees
RWRobert Wesolowski
Robert Wesolowski
ABAditya Bardia
Aditya Bardia
HRHope Rugo
Hope Rugo
1040 Background: The majority of women with ER+ MBC develop resistance to ET. ET plus a CDK4/6 inhibitor (CDKi 4/6) demonstrate improved progression-free survival (PFS) in first/later line MBC. Preclinical evidence in PI3K mutant cell-line xenografts (PIK3CA) supported developing a triplet combination of gedatolisib (G), a dual inhibitor of PI3K/mammalian target of rapamycin (mTOR), with CDKi 4/6 palbociclib (P)+letrozole (L) or fulvestrant (F) for patients (pts) with ER+/HER2- MBC. Methods: This ongoing dose escalation/expansion study in pts with ER+/HER2- MBC, in first/later line MBC, evaluates dose-limiting toxicities/recommended phase 2 dose (DLTs/RP2D) for triplet regimens of G+P+L or G+P+F. A 3-arm expansion investigates objective response rate (ORR) compared to historical controls of Arm A) G+P+L in first-line, B) G+P+F in pts with no prior CDKi 4/6 in second-line and C) G+P+F in pts with prior CDKi 4/6. Pts receive G (180 mg IV/week) combined with P+L or P+F at standard of care doses. Secondary endpoints include safety, ORR, PFS, and pharmacokinetics (PK); exploratory endpoints include genomic analysis of PI3K/mTOR pathway. Results: 35 pts received G at RP2D of 180 mg with P+L (n = 15) or P+F (n = 20). Median numbers of prior therapies: G+P+L: 2 (range: 1-2); G+P+F: 1 (range 1-3). Most common (≥50%), drug-related adverse events (%): G+P+L: nausea (80), stomatitis (73), fatigue (60), neutropenia (60), dysgeusia (53); G+P+F: stomatitis (70), fatigue (70), neutropenia (60), nausea (60), dysgeusia (55). Cycle 1 DLTs: G+P+L: grade (gr) 3 neutropenia (n = 2), gr 3 stomatitis (n = 1), gr 3 febrile neutropenia (n = 1); G+P+F: gr 3 stomatitis (n = 2), gr 3 mucositis (n = 1), gr 3 abdominal pain (n = 1). Preliminary stable disease/partial response: G+P+L: 53%/33%; G+P+F: 55%/20%. No PK interactions were observed. PIK3CA and ER mutation status from circulating free deoxyribonucleic acid and duration of response will be reported. Genomic analysis of tumor tissue is underway. Conclusions: G can be combined with P+L or P+F with manageable toxicity and promising preliminary antitumor activity. Dose escalation is completed and expansion is ongoing. Clinical trial information: NCT02684032.

31 August 2021 in Future Oncology
Verified
Journal Article
Open access
KDKendra DeBusk
Kendra DeBusk
SAShaun Abeysinghe
Shaun Abeysinghe
AVAdrian Vickers
Adrian Vickers
ANAnubhav Nangia
Anubhav Nangia
JBJudith Bell
Judith Bell
MBMatthew T Blahna
Matthew T Blahna
Aim: A systematic literature review and network meta-analysis of randomized controlled trials in patients receiving therapy for HER2+ unresectable/metastatic breast cancer after ≥1 HER2-directed th... Lay abstract Although several therapies are used in HER2-positive metastatic breast cancer, direct head-to-head comparisons of these therapies are lacking. We conducted a network meta-analysis, a w...